Jaguar Health, a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced that it has entered into a collaboration agreement with Seed Mena Businessmen Services LLC for Equilevia, Jaguar’s non-prescription, personalized, premium product for total gut health in equine athletes.
Based in Dubai in the United Arab Emirates, SEED is affiliated with Seed Group, a diversified group of companies under the umbrella of The Private Office of His Royal Highness Sheikh Saeed Bin Ahmed Al Maktoum establishing strategic partnerships with multinational companies from around the globe in an aim to leverage Seed Group’s network to support potential business expansion in the MENA region.
Equilevia contains ingredients isolated and purified from the medicinal Croton lechleri tree, which is sustainably harvested from the rainforest. Equilevia acts locally in the gut. Gut health is of critical importance in competitive horses, as conditions such as ulcers can meaningfully impair equine athlete performance, and colic can lead to the death of an otherwise healthy horse in a matter of hours.
According to a third-party 2005 study, as many as 55% of performance horses have both colonic and gastric ulcers, and 97% of performance horses have either a gastric or a colonic ulcer.
In 2017, 7,399 horses and 1,437 equine athletes from the UAE Equestrian & Racing Federation, which supervises the organization of equestrian and racing activities in the UAE, are registered with The International Federation for Equestrian Sports, the international governing body of equestrian athletics.
Approximately 2,000 active endurance-racing horses and 87 racing stables in the UAE were listed by the Emirates Equestrian Federation in 2012. Jaguar has tested Equilevia for safety and wellness in both racing horses and horses in training. The results of testing in actively racing horses resulted in more top placements and greater purses for horses given Equilevia than for horses on placebo, as well as observations of improved equine wellness.
According to the terms of the Agreement, Jaguar will pay SEED an ongoing percentage of revenue generated from any clients or partners introduced to Jaguar by SEED, and the agreed-upon revenue percentage increases after the first one-million dollars of revenue.